Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic IT Chemotherapy to Prevent High-Grade CAR T-Cell-Associated Neurotoxicity Syndrome
NCT06895473Phase 2Recruiting
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jun 2025
- Primary completion
- Apr 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cytarabine, methotrexate and hydrocortisone in immune effector cell-associated neurotoxicity syndrome (ICANS), sponsored by OHSU Knight Cancer Institute. Primary endpoint: Incidence of American Society for Transplantation and Cellular Therapy (ASTCT) >= grade 3 immune-effector cell associated neurotoxicity syndrome (ICANS) at Day 30. Started Jun 2025; status: recruiting.
02
Drugs
cytarabinemethotrexatehydrocortisone
03
Conditions
immune effector cell-associated neurotoxicity syndrome (ICANS)
Beyond the preview
Go deeper on NCT06895473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06895473.